Please assess the completion status of the following clinical trial:

Trial Title: A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. At least 18 years of age.~2. Histologically confirmed diagnosis of advanced solid or haematological malignancy not amenable to standard treatment.~3. Pharmacological treatment attempt justified~4. Preserved major organ functions, i.e:~   * B-Leukocyte count ≥ 3.0 x 109/L~  * B-Neutrophil count ≥ 1.5 x 109/L~  * B-Platelet count ≥ 75 x109/L~  * B-Haemoglobin ≥ 100 g/L (transfusions are allowed)~  * P-Total bilirubin level ≤ 1.5 times the upper institutional limit of the normal (i.e. reference) range~  * P-ASAT or P-ALAT ≤ 2.5 times upper institutional limit of the normal range, ≤5 times if liver metastases have been documented~  * P-Creatinine ≤ 1.5 times upper institutional limit of the normal range~5. Females of childbearing potential should use adequate contraception (oral or injectable contraceptives, hormone releasing intrauterine device) throughout the study period.~6. Signed written informed consent.~Exclusion Criteria:~1. Ongoing infection or other major recent or ongoing disease that, according to the investigator, poses an unacceptable risk to the patient~2. Known malignancy in CNS~3. Prior anti-tumour therapy within 4 weeks from enrolment (6 weeks for nitrosurea and MitC).~4. Pregnancy or lactation~5. Current participation in any other interventional clinical trial~6. Performance status \> ECOG 2 after optimization of analgesics~7. Life expectancy less than 3 months~8. Contraindications to the investigational product, e.g. known or suspected hypersensitivity.~9. Lack of suitability for participation in the trial, for any reason, as judged by the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AXL1717 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).